False negative bone scintigraphy in a patient with primary breast cancer: A possible transient phenomenon of bisphosphonate (alendronate) treatment

Demirkan B., Baskan Z., Alacacioglu A., Gorken İ., BEKİŞ R., Ada E., ...Daha Fazla

TUMORI, cilt.91, sa.1, ss.77-80, 2005 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 91 Sayı: 1
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1177/030089160509100115
  • Dergi Adı: TUMORI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.77-80
  • Anahtar Kelimeler: bisphosphonate, bone metastasis, breast cancer, 99mTc-MDP bone scan, WOMEN, PHARMACOKINETICS, DIPHOSPHONATE, METASTASES, TC-99M-MDP
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Breast cancer is the most common cancer and the second leading cause of cancer deaths among women in developed countries. Bone is a frequent site of metastatic disease with a stage-dependent incidence. Most women with breast cancer are at risk of osteoporosis due to their age or their breast cancer treatment. Scintigraphy enables imaging of the entire skeleton with high sensitivity but limited specificity. The false positive rate varies from 1.6% to as high as 22%, while the false negative rate varies from 0.96% to 13%.